Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human T cell lymphotropic virus-associated leukemia/lymphoma.

Lee Ratner1

  • 1Division of Molecular Oncology, Washington University, 660 South Euclid Avenue, Saint Louis, MO 63110, USA. lratner@im.wustl.edu

Current Opinion in Oncology
|August 12, 2005
PubMed
Summary

Human T cell lymphotropic virus-associated leukemia/lymphoma (HTLV) treatments are evolving. Research highlights the role of the Tax oncoprotein and NF-kappaB pathways in disease development and therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: Synchronous Manifestations of Kaposi Sarcoma Herpesvirus-Associated Disorders.

Cancer reports (Hoboken, N.J.)·2026
Same author

Viral oncogenes drive biphenotypic lymphoproliferative malignancy in transgenic mice.

Scientific reports·2025
Same author

Corrigendum to "The SMAC mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and SMAC" [Leuk. Res., 36(2011) 784-90].

Leukemia research·2025
Same author

Role of the CTCF binding site in Human T-Cell Leukemia Virus-1 pathogenesis.

PLoS pathogens·2025
Same author

Single-Cell Transcriptomic Analysis of Kaposi Sarcoma.

PLoS pathogens·2025
Same author

Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Human T cell lymphotropic virus type 1 (HTLV-1) is a retrovirus linked to specific leukemias and lymphomas.
  • Understanding the molecular mechanisms driving HTLV-1-associated malignancies is crucial for therapeutic development.

Purpose of the Study:

  • To review the pathophysiologic basis of HTLV-associated leukemia/lymphoma.
  • To summarize current and emerging therapeutic strategies for these conditions.

Main Methods:

  • Literature review of studies on HTLV-1 pathophysiology and treatment.
  • Analysis of recent findings on novel therapeutic agents and approaches.

Main Results:

  • Recent studies have investigated allogeneic stem cell transplantation, arsenic trioxide, and bortezomib.

Related Experiment Videos

  • The oncoprotein Tax and nuclear factor-kappaB (NF-kappaB) pathways are critical in HTLV-1-induced T cell leukemia/lymphoma.

    • Conclusions:

    • Targeting Tax and NF-kappaB pathways offers rational therapeutic strategies for HTLV-1-associated leukemia/lymphoma.
    • These findings provide a model for other NF-kappaB-driven hematopoietic malignancies.